The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

Thus, CT-996 could potentially be dosed without regard to meal timing, thereby affording greater dosing flexibility for ...

The upcoming EASD meeting will feature new data on once-weekly insulin and GLP-1 drugs and joint society collaborations ...

Shares of Novo Nordisk and Eli Lilly took a hit after Swiss pharma giant Roche posted positive results for its experimental ...

Keep an eye on these stocks as the weight loss drug market stabilizes and Uncle Sam steps into the pricing picture.

That's why its data update from its CT-996 program on July 16 made such a splash in the market. Per an interim data update from a phase 1 clinical trial, patients treated with CT-996 for just four ...

Roche RHHBY announced positive top-line results from an early-stage study on its experimental obesity candidate CT-996. The study is a multi-part, multi-cohort phase I randomized, double-blind ...

On July 17, Roche announced positive top-line results from its phase 1 clinical trial evaluating CT-996 in treating type 2 diabetes and obesity. Like Novo Nordisk's blockbuster drugs Ozempic and ...

Roche has a market cap of more than $250 billion, is a big name in healthcare, and will be a formidable rival for Novo ...

Patients taking the investigational treatment, CT-996, achieved average weight loss of 7.3% after four weeks, Roche said in a release, adding that trial data support once-daily dosing of the pill.